Compare Nasdaq Inc (NDAQ) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Tilray Brands Inc — how do they compare? Nasdaq Inc trades at $95 (market cap $52.67B), while Tilray Brands Inc trades at $4.25 (market cap $577.15M). The key difference: Nasdaq Inc is far larger — about 91.3× Tilray Brands Inc's market cap, and Nasdaq Inc pays a 1.23% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| NDAQ | TLRY | |
|---|---|---|
Market Cap | $52.67B | $577.15M |
Sector | Financials | Health |
52-Week High | $100.98 | $21.00 |
52-Week Low | $76.85 | $3.88 |
Enterprise Value | $59.12B | $744.29M |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.04, down 1.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding the $0.984 estimate. Revenue grew to $8.26B in 2025, and net income margin improved to 22.52%. Recent news highlights strategic acquisitions like Dasseti to enhance AI capabilities.
The outlook is positive with a consensus price target of $109.20, implying 15% upside. Key opportunities include continued earnings growth and expansion in data-driven investment technology. Risks involve market volatility and execution of acquisition integration. Analyst sentiment is bullish with 61% buy ratings.
TLRY trades at $4.30, down 4.44% with a bearish technical outlook. The company reported record fiscal 2026 revenue of $915M but continues to post significant losses with a -13.27% net margin. Recent news highlights expansion in spirits distribution and medical cannabis production, though regulatory uncertainty weighs on sentiment. The stock trades below book value with a P/S of 0.51 and P/B of 0.36, suggesting potential undervaluation despite profitability challenges.
TLRY presents a high-risk opportunity with mixed signals. The discounted valuation and expanding beverage/alcohol business offer upside potential, but persistent losses, negative cash flow, and cannabis regulatory delays create substantial headwinds. Analyst consensus leans cautious with 65% hold ratings, reflecting the stock's speculative nature amid ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
